Regulatory Bayer plans filings for cardiac amyloidosis imaging agent PharmaphorumArmed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.CardiovascularRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaphorum Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche buys AI-powered diagnostics player PathAINext: Angelini inks $4.1B Catalyst buy to enter US rare disease market Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
